105 related articles for article (PubMed ID: 35967350)
1. Reduced binding activity of vaccine serum to omicron receptor-binding domain.
Li M; Weng S; Wang Q; Yang Z; Wang X; Yin Y; Zhou Q; Zhang L; Tao F; Li Y; Jia M; Yang L; Xin X; Li H; Kang L; Wang Y; Wang T; Li S; Kong L
Front Immunol; 2022; 13():960195. PubMed ID: 35967350
[TBL] [Abstract][Full Text] [Related]
2. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
3. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.
Bartsch YC; Atyeo C; Kang J; Cai Y; Chen B; Gray KJ; Edlow AG; Alter G
Am J Obstet Gynecol; 2022 Sep; 227(3):493.e1-493.e7. PubMed ID: 35430229
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
Front Immunol; 2022; 13():908478. PubMed ID: 35844601
[TBL] [Abstract][Full Text] [Related]
5. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
[TBL] [Abstract][Full Text] [Related]
6. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.
Trombetta CM; Piccini G; Pierleoni G; Leonardi M; Dapporto F; Marchi S; Andreano E; Paciello I; Benincasa L; Lovreglio P; Buonvino N; Decaro N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Rappuoli R; Molesti E; Manenti A; Montomoli E
Commun Biol; 2022 Sep; 5(1):903. PubMed ID: 36056181
[TBL] [Abstract][Full Text] [Related]
7. Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of
Kim WS; Kim JH; Lee J; Ka SY; Chae HD; Jung I; Jung ST; Na JH
Bioengineering (Basel); 2022 Nov; 9(11):. PubMed ID: 36354581
[TBL] [Abstract][Full Text] [Related]
8. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
9. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
10. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
11. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
[TBL] [Abstract][Full Text] [Related]
12. Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults.
Kared H; Wolf AS; Alirezaylavasani A; Ravussin A; Solum G; Tran TT; Lund-Johansen F; Vaage JT; Nissen-Meyer LS; Nygaard UC; Hungnes O; Robertson AH; Næss LM; Trogstad L; Magnus P; Munthe LA; Mjaaland S
Nat Commun; 2022 Jul; 13(1):4165. PubMed ID: 35851055
[TBL] [Abstract][Full Text] [Related]
13. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
Xu K; Gao P; Liu S; Lu S; Lei W; Zheng T; Liu X; Xie Y; Zhao Z; Guo S; Tang C; Yang Y; Yu W; Wang J; Zhou Y; Huang Q; Liu C; An Y; Zhang R; Han Y; Duan M; Wang S; Yang C; Wu C; Liu X; She G; Liu Y; Zhao X; Xu K; Qi J; Wu G; Peng X; Dai L; Wang P; Gao GF
Cell; 2022 Jun; 185(13):2265-2278.e14. PubMed ID: 35568034
[TBL] [Abstract][Full Text] [Related]
14. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
Li Y; Wang X; Jin J; Ma Z; Liu Y; Zhang X; Su B
J Med Virol; 2022 Aug; 94(8):3998-4004. PubMed ID: 35474581
[TBL] [Abstract][Full Text] [Related]
15. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
[TBL] [Abstract][Full Text] [Related]
16. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
17. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
Front Immunol; 2022; 13():871874. PubMed ID: 35898497
[TBL] [Abstract][Full Text] [Related]
18. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
Mei S; Fan Z; Liu X; Zhao F; Huang Y; Wei L; Hu Y; Xie Y; Wang L; Ai B; Liang C; Xu F; Guo F
Front Immunol; 2022; 13():911164. PubMed ID: 35935962
[TBL] [Abstract][Full Text] [Related]
20. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
